Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Equity Average (2016 - 2026)

Neuroone Medical Technologies filings provide 13 years of Equity Average readings, the most recent being $5.9 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 189.96% to $5.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.9 million, a 189.96% increase, with the full-year FY2025 number at $3.9 million, up 11.64% from a year prior.
  • Equity Average hit $5.9 million in Q1 2026 for Neuroone Medical Technologies, down from $6.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.5 million in Q1 2022 to a low of $1.9 million in Q4 2024.
  • Median Equity Average over the past 5 years was $5.3 million (2023), compared with a mean of $6.2 million.
  • Biggest five-year swings in Equity Average: plummeted 64.78% in 2024 and later soared 297.78% in 2025.
  • Neuroone Medical Technologies' Equity Average stood at $8.9 million in 2022, then crashed by 39.99% to $5.3 million in 2023, then tumbled by 64.78% to $1.9 million in 2024, then skyrocketed by 258.62% to $6.7 million in 2025, then dropped by 12.61% to $5.9 million in 2026.
  • The last three reported values for Equity Average were $5.9 million (Q1 2026), $6.7 million (Q4 2025), and $7.6 million (Q3 2025) per Business Quant data.